Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
denosumab + gemcitabine + platinum
- Development stage
- Unknown
- Lead developer
- Gruppo Oncologico Nord Ovest
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Intravenous
01
Overview
Denosumab + gemcitabine + platinum is a combination chemo-immunotherapy regimen being evaluated by the Gruppo Oncologico del Nord-Ovest (GONO) for the treatment of recurrent or metastatic Epstein-Barr Virus (EBV)-related nasopharyngeal carcinoma (NPC). The regimen utilizes denosumab, a monoclonal antibody targeting the Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL), as an immunologic primer to modulate the tumor microenvironment before and during standard chemotherapy with gemcitabine and a platinum agent (cisplatin or carboplatin). This approach aims to exploit the RANK/RANKL pathway's role in immune evasion in EBV-driven malignancies to improve clinical outcomes in patients with advanced NPC.
- Other names
- Denosumab + Gemcitabine + CisplatinDenosumab + Gemcitabine + Carboplatin
02
Targets
DNARANKL (Receptor Activator for Nuclear Factor-kappa B Ligand)
Beyond the preview
Go deeper on denosumab + gemcitabine + platinum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on denosumab + gemcitabine + platinum.